We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Daniel J. Min
Daniel J. Min
Products
PRODUCTS
Medical Products Laboratories, Inc.
Daniel J. Min
Price:
$117.00
View
i3 Pharmaceuticals, LLC
Amit Kokate
,
Daniel J. Min
, and
Janet A. Rajan
Price:
$117.00
View
Austarpharma, LLC
Daniel J. Min
Price:
$117.00
View
Northern VA Compounders, PLLC
Jonathan Matrisciano
and
Daniel J. Min
Price:
$117.00
View
Mandell's Clinical Pharmacy
Sayyem H. Akbar
,
Adetutu Gidado
, and
Daniel J. Min
Price:
$117.00
View
Ferring Production, Inc.
Daniel J. Min
,
David A. Oluwo
, and
Janet A. Rajan
Price:
$117.00
View
I3 Pharmaceuticals, LLC
Daniel J. Min
and
David A. Oluwo
Price:
$117.00
View
SigmaPharm Laboratories, LLC
Marcellinus Dordunoo
and
Daniel J. Min
Price:
$117.00
View
Acino Products, LLC
Daniel J. Min
and
David A. Oluwo
Price:
$117.00
View
Dercher Enterprises, Inc., DBA Gordon Laboratories
Daniel J. Min
and
David A. Oluwo
Price:
$117.00
View
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
From QSR to QMSR: Meeting FDA’s New Requirements
FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
